Lo-Zumandimine

Birth Control, Acne Vulgaris, Folate supplementation therapy + 9 more

Treatment

20 Active Studies for Lo-Zumandimine

What is Lo-Zumandimine

Drospirenone

The Generic name of this drug

Treatment Summary

Drospirenone is a hormone used in combination with estrogen in birth control pills like Yaz and Estetrol. It can also be used to treat acne and PMDD. It has been linked to an increased risk of venous thromboembolism, but this has not been fully proven. The FDA states that the risk of thromboembolic events is lower than the risk during pregnancy or postpartum, so this should be taken into account when deciding whether to use this medication.

Yasmin

is the brand name

image of different drug pills on a surface

Lo-Zumandimine Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Yasmin

Drospirenone

2001

64

Effectiveness

How Lo-Zumandimine Affects Patients

Drospirenone prevents pregnancy by stopping the growth of eggs in the ovaries and preventing ovulation. It also has anti-androgen effects, which can improve acne and hirsutism. Taking drospirenone combined with ethinyl estradiol has been found to have positive effects on cholesterol levels. Additionally, due to its similarity to natural progesterone, it may cause fewer side effects related to progesterone than other contraceptive drugs. However, taking drospirenone can increase the risk of developing venous thromboembolism or other cardiovascular events, especially in those who are smokers or are 35 and older

How Lo-Zumandimine works in the body

Drospirenone and ethinyl estradiol work together to prevent pregnancy. They do this by stopping the release of hormones that trigger ovulation. They also change the consistency of cervical mucus, making it harder for sperm to reach an egg. Drospirenone is related to a diuretic drug, which makes your body get rid of extra salt and water. It also works against androgens, which can lead to acne and excessive hair growth. Finally, it reduces swelling in sebaceous follicles, which helps to prevent acne.

When to interrupt dosage

The amount of Lo-Zumandimine is contingent upon the determined illness, including moderate to serious indications, Menopause and Post-Menarche. The dosage also shifts as indicated by the technique of administration (e.g. Tablet, film coated - Oral or Oral) mentioned in the table beneath.

Condition

Dosage

Administration

Birth Control

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral

moderate to severe symptoms

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral

N-Cadherins

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral

Hormonal Contraception

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral

Vasomotor System

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral

Acne Vulgaris

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral

Adherence to Oral Contraceptive Therapy

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral

Atrophic

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral

Post-Menarche

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral

Atrophy of vulva

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral

Folate supplementation therapy

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral

Hot flashes

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated - Oral, Tablet, film coated, Oral, Kit - Oral, Tablet, Tablet - Oral

Warnings

Lo-Zumandimine Contraindications

Condition

Risk Level

Notes

Chronic Kidney Disease

Do Not Combine

Venous Thrombosis

Do Not Combine

Neoplasms, Hormone-Dependent

Do Not Combine

Migraine with Aura

Do Not Combine

Porphyrias

Do Not Combine

Breast

Do Not Combine

suspected pregnancy

Do Not Combine

Breast Milk Production

Do Not Combine

Metrorrhagia

Do Not Combine

Hypersensitivity

Do Not Combine

Liver Failure, Acute

Do Not Combine

Acute Kidney Injury

Do Not Combine

Deep Vein Thrombosis (DVT)

Do Not Combine

Vision Loss

Do Not Combine

Endometrial Hyperplasia

Do Not Combine

Tobacco Use

Do Not Combine

Liver Function Tests

Do Not Combine

Thrombophilia

Do Not Combine

Thromboembolism

Do Not Combine

high risk of arterial thrombotic disease

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

Liver Neoplasms

Do Not Combine

Adrenal Insufficiency

Do Not Combine

Thrombosis

Do Not Combine

Breast

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

There are 20 known major drug interactions with Lo-Zumandimine.

Common Lo-Zumandimine Drug Interactions

Drug Name

Risk Level

Description

Tranexamic acid

Major

Drospirenone may increase the thrombogenic activities of Tranexamic acid.

Acetohexamide

Minor

The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Drospirenone.

Agmatine

Minor

The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Agmatine.

Aliskiren

Minor

The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Aliskiren.

Anisodamine

Minor

The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Anisodamine.

Lo-Zumandimine Toxicity & Overdose Risk

The most toxic dose of drospirenone for rats is greater than 2000mg/kg. Signs of drospirenone overdose may include nausea, irregular bleeding, and disturbances in the levels of sodium and potassium in the blood. In cases of overdose, the levels of these substances should be monitored closely, as well as for signs of metabolic acidosis and high potassium levels.

Lo-Zumandimine Novel Uses: Which Conditions Have a Clinical Trial Featuring Lo-Zumandimine?

At present, 104 active studies are being conducted to evaluate the utility of Lo-Zumandimine for Acne Vulgaris, Post-Menarche and N-Cadherins.

Condition

Clinical Trials

Trial Phases

N-Cadherins

0 Actively Recruiting

moderate to severe symptoms

0 Actively Recruiting

Folate supplementation therapy

0 Actively Recruiting

Acne Vulgaris

0 Actively Recruiting

Atrophy of vulva

1 Actively Recruiting

Not Applicable

Hormonal Contraception

0 Actively Recruiting

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3

Post-Menarche

0 Actively Recruiting

Adherence to Oral Contraceptive Therapy

0 Actively Recruiting

Birth Control

22 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Atrophic

4 Actively Recruiting

Phase 4, Not Applicable

Vasomotor System

0 Actively Recruiting

Patient Q&A Section about lo-zumandimine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Lo-Zumandimine have estrogen?

"Lo-Zumandimine is a combined oral contraceptive (COC) that contains the synthetic forms of the female hormones estrogen and progesterone. It is indicated for use by women to prevent pregnancy, to treat symptoms of premenstrual dysphoric disorder (PMDD), and to treat moderate acne in women who are at least 14 years old and have started having their period."

Answered by AI

What kind of birth control is Zumandimine?

"This medication is a combination of an estrogen and a progestin. This product is used to prevent pregnancy."

Answered by AI

Is Lo-Zumandimine the same as Yaz?

"This medication is used to prevent pregnancy. It may also be used to treat premenstrual dysphoric disorder (PMDD) or acne in women who are using birth control pills.

This medication is used to prevent pregnancy. It may also be used to treat premenstrual dysphoric disorder (PMDD) or acne in women who are using birth control pills."

Answered by AI

Is Lo-Zumandimine good for acne?

"The drug Lo-Zumandimine is indicated for the treatment of moderate acne in women 14 years of age or older, who do not have any known conditions that would make taking oral contraception unsafe, and who have started having their period."

Answered by AI

Clinical Trials for Lo-Zumandimine

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Have you considered Lo-Zumandimine clinical trials?

We made a collection of clinical trials featuring Lo-Zumandimine, we think they might fit your search criteria.
Go to Trials
Image of University of California, San Diego in La Jolla, United States.

Lidocaine for Pain Control in Birth Control

18 - 50
Female
La Jolla, CA

The goal of this research study is to learn more about how different uses of a numbing medication might affect pain levels while getting an IUD placed. The investigators are also studying participants opinions of their clinicians' empathy. The investigators are inviting patients who arrive at their clinic visit seeking an IUD. Usually, at University of California, San Diego (UCSD), for patients who have never delivered a baby, clinicians use a buffered paracervical block for before IUD placement. The purpose of this research study is to investigate whether a "buffered" (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) paracervical block (numbing medication given on both sides of the cervix) is effective in reducing pain during IUD placement in individuals with prior C-sections, the difference between buffered and unbuffered for nulliparous patients, and whether a medicated gel reduces pain with the paracervical block.

Recruiting
Paid Trial

University of California, San Diego

Sheila K Mody, MD, MPH

Have you considered Lo-Zumandimine clinical trials?

We made a collection of clinical trials featuring Lo-Zumandimine, we think they might fit your search criteria.
Go to Trials
Image of Calabasas Pharmacy in Calabasas, United States.

Electronic Health Record Platform for Birth Control

18 - 51
Female
Calabasas, CA

Hormonal contraceptives are medications that require a prescription, traditionally from a physician or advanced practice provider. Over the past decade, pharmacists have gained the authority to prescribe contraceptives in many states, allowing patients to access these medications directly in pharmacies without first seeing another healthcare provider. The Pharmacist Resource to Implement Services as Modules (PRISM) is an Electronic Health Record platform designed to streamline workflows and provide clinical decision support, making it easier and safer to deliver clinical services in community pharmacies. This pilot study will evaluate patient-reported outcomes for women receiving contraceptive services from pharmacists using the PRISM platform at five community pharmacies across the United States over a 12-week period. The study will assess the quality of care, contraception continuation and failure rates, side effect rates, preventative healthcare utilization, and overall patient experience with pharmacy contraceptive services.

Waitlist Available
Has No Placebo

Calabasas Pharmacy (+4 Sites)

OvaryIt, LLC

Image of Noll Laboratory in University Park, United States.

Estradiol and Elagolix for Menopause

42 - 64
Female
University Park, PA

The frequency and severity of heat waves has increased in the last decades. Older adults (over 65 years) have impaired responses to heat stress making them at increased risk for adverse events. Previous heat waves report that women over 65 experience worse health outcomes than any other age group and age matched men. Aging and reproductive hormones, specifically estrogen, independently alter responses to heat stress. However, the combined effects of low estrogen following menopause and aging on the response to heat stress are unknown. In this study, the investigators will identify the role of estrogen in pre and post menopausal women on thermoregulatory responses to heat stress.

Phase 4
Recruiting

Noll Laboratory

W. Larry Kenney, Ph.D.

Have you considered Lo-Zumandimine clinical trials?

We made a collection of clinical trials featuring Lo-Zumandimine, we think they might fit your search criteria.
Go to Trials